Please select the option that best describes you:

How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?   

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with primary refractory vs other relapsing disease?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution